BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31007857)

  • 1. Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.
    Ghosh GC; Ghosh RK; Bandyopadhyay D; Chatterjee K; Aneja A
    Heart Views; 2018; 19(3):88-98. PubMed ID: 31007857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
    Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
    Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
    Yuriivna Osovska N; Vitaliivna Kuzminova N
    Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging clinical role of ranolazine in the management of angina.
    Vadnais DS; Wenger NK
    Ther Clin Risk Manag; 2010 Oct; 6():517-30. PubMed ID: 21063462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
    Banerjee K; Ghosh RK; Kamatam S; Banerjee A; Gupta A
    Int J Cardiol; 2017 Jan; 227():556-564. PubMed ID: 27838121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.
    De Vecchis R; Ariano C; Giasi A; Cioppa C
    Minerva Cardioangiol; 2018 Jun; 66(3):349-359. PubMed ID: 28497941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
    Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
    Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.
    Miles RH; Passman R; Murdock DK
    Am J Cardiol; 2011 Sep; 108(5):673-6. PubMed ID: 21726841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
    Thadani U
    Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine for the management of coronary artery disease.
    Cheng JW
    Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
    Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
    Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris.
    Aldakkak M; Stowe DF; Camara AK
    Clin Med Insights Ther; 2013 Jan; 2013(5):1-14. PubMed ID: 24574825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
    Verrier RL; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Zeng D; Belardinelli L
    Heart Rhythm; 2013 Jan; 10(1):121-7. PubMed ID: 22985658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine: a potential new treatment for chronic stable angina.
    Anderson JR; Khou S; Nawarskas JJ
    Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.